Prophylaxis and treatment of deep-vein thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 3 SUPPL. 1, 2000, Pages 47-52

  Breddin, H K ^a  

^a Intl Inst Thromb/Vasc Dis eV   (Germany)

Author keywords

Bleeding risk; Fibrinogen uptake test; General surgery; Gynecology; Low molecular weight heparins; Thrombosis prophylaxis; Treatment of deep vein thrombosis; Venography

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; FIBRINOGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; PLACEBO; REVIPARIN; TINZAPARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GENERAL SURGERY; GYNECOLOGIC SURGERY; HUMAN; META ANALYSIS; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS;

CLINICAL TRIALS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; VENOUS THROMBOSIS;

EID: 0033816612     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin)
2. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: A multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group
3. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216)
4. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery
5. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis
6. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial
7. Prevention of thromboembolism in minimal invasive interventions and brief inpatient treatment. Results of a multicenter, prospective, randomized, controlled study with a low molecular weight heparin
8. Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery
9. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial
10. Thromboseprophylaxe in der Abdominalchirurgie. Vergleich der Wirksamkeit und Vertraglichkeit von niedermolekularem und unfraktioniertem Heparin
11. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery
12. Thromboseprophylaxe in der Gynakologie: Doppelblind-Vergleich zwischen niedermolekularem (LMWH) und unfraktioniertem (UFH) Heparin [Thrombosis prophylaxis in gynecology: A randomized double-blind study between low molecular weight heparin (LMWH) and unfractionated beparin (UFH)]
13. Low-Dose-Heparin versus niedermolekulares Heparin zur Thromboseprophylaxe in der operativen gynaekologischen Onkologie [Prevention of postoperative venous thrombosis. A randomised trial comparing low-dose heparin and low molecular weight heparin in gynaecological oncology]
14. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis
15. Low molecular weight heparin (KAB1 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfrac-donated heparin
16. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis
17. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery
18. Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery
19. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial
20. Prophylaxis of thromboembolism in general surgery: Comparison between standard heparin and Fragmin
21. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group
22. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
23. Enoxaparin in the prevention of deep venous thrombosis after major surgery: Multicentric study. The Italian Study Group
24. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery
25. Thromboprophylaxis in colorectal surgery-A randomized trial comparing low dose heparin to enoxaparin
26. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
27. Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group
28. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group
29. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study
30. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
31. Efficacy and tolerance of Fraxiparine in the prevention of deep vein thrombosis in general surgery performed with medullar conduction anesthesia
32. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin
33. Die Thromboembolieprophylaxe und der Chirurg-zwei Risikofaktoren der postoperativen Blutung? [Thromboembolism prophylaxis and the surgeon-two risk factors of postoperative bleeding?]
34. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis
35. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg
36. Adjusted versus fixed doses of the low-molecular-weight heparin fragrain in the treatment of deep vein thrombosis. Fragmin-Study Group
37. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
38. A randomized trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis
39. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
40. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial
41. Treatment of deep venous thrombosis with a very low molecular weight heparin fragment (CY 222)
42. An open trial of enoxaparin in the treatment of deep vein thrombosis of the leg
43. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
44. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis
45. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis
46. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis
47. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
48. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
49. The Columbus Investigators Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
50. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treat-merit of deep venous thrombosis